(4-(hydroxymethyl)-2-isopropylthiazolyl)methyl 4-nitrophenyl carbonate | 165315-49-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (4-(hydroxymethyl)-2-isopropylthiazolyl)methyl 4-nitrophenyl carbonate
• 英文别名: 2-Isopropyl-4-(p-nitrophenyloxycarbonyloxymethyl)thiazole；(4-nitrophenyl) (2-propan-2-yl-1,3-thiazol-4-yl)methyl carbonate
• CAS: 165315-49-1
• 化学式: C₁₄H₁₄N₂O₅S
• 分子量: 322.342
• InChiKey: LZKKYACAMKUENE-UHFFFAOYSA-N

物化性质

• 沸点：
  474.1±45.0 °C(Predicted)
• 密度：
  1.350±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  123
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  L-丙氨酸甲酯盐酸盐 、 (4-(hydroxymethyl)-2-isopropylthiazolyl)methyl 4-nitrophenyl carbonate 在 N-甲基吗啉 作用下， 以 氯仿 为溶剂， 反应 16.0h， 以94%的产率得到N-<<(2-isopropyl-4-thiazolyl)methoxy>carbonyl>-L-alanine methyl ester
  参考文献：
  名称：

  Discovery of Ritonavir, a Potent Inhibitor of HIV Protease with High Oral Bioavailability and Clinical Efficacy

  摘要：

  The structure-activity studies leading to the potent and clinically efficacious HIV protease inhibitor ritonavir are described. Beginning with the moderately potent and orally bioavailable inhibitor A-80987, systematic investigation of peripheral (P3 and P2') heterocyclic groups designed to decrease the rate of hepatic metabolism provided analogues with improved pharmacokinetic properties after oral dosing in rats. Replacement of pyridyl groups with thiazoles provided increased chemical stability toward oxidation while maintaining sufficient aqueous solubility for oral absorption, Optimization of hydrophobic interactions with the HIV protease active site produced ritonavir, with excellent in vitro potency (EC50 = 0.02 mu M) and high and sustained plasma concentrations after oral administration in four species. Details of the discovery and preclinical development of ritonavir are described.

  DOI：

  10.1021/jm970636+
• 作为产物：
  描述：

  2-异丙基噻唑-4-羧酸乙酯 在 N-甲基吗啉 、 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 、 二氯甲烷 、 甲苯 为溶剂， 反应 4.0h， 生成 (4-(hydroxymethyl)-2-isopropylthiazolyl)methyl 4-nitrophenyl carbonate
  参考文献：
  名称：

  Discovery of Ritonavir, a Potent Inhibitor of HIV Protease with High Oral Bioavailability and Clinical Efficacy

  摘要：

  The structure-activity studies leading to the potent and clinically efficacious HIV protease inhibitor ritonavir are described. Beginning with the moderately potent and orally bioavailable inhibitor A-80987, systematic investigation of peripheral (P3 and P2') heterocyclic groups designed to decrease the rate of hepatic metabolism provided analogues with improved pharmacokinetic properties after oral dosing in rats. Replacement of pyridyl groups with thiazoles provided increased chemical stability toward oxidation while maintaining sufficient aqueous solubility for oral absorption, Optimization of hydrophobic interactions with the HIV protease active site produced ritonavir, with excellent in vitro potency (EC50 = 0.02 mu M) and high and sustained plasma concentrations after oral administration in four species. Details of the discovery and preclinical development of ritonavir are described.

  DOI：

  10.1021/jm970636+

文献信息

• [EN] RETROVIRAL PROTEASE INHIBITING COMPOUNDS<br/>[FR] COMPOSES INHIBANT DES PROTEASES RETROVIRALES
  申请人：ABBOTT LABORATORIES

  公开号：WO1994014436A1

  公开（公告）日：1994-07-07

  (EN) A retroviral protease inhibiting compound of formula (A) is disclosed.(FR) L'invention se rapporte à un composé inhibant des protéases rétrovirales, qui est présenté par la formule (A).

  一种抑制反转录病毒蛋白酶的化合物公式（A）已被披露。(法语)本发明涉及一种通过公式（A）表示的抑制反转录病毒蛋白酶的化合物。
• Retroviral protease inhibiting compounds
  申请人：Abbott Laboratories

  公开号：US05616720A1

  公开（公告）日：1997-04-01

  A retroviral protease inhibiting compound of the formula: ##STR1## is disclosed.

  公开了一种具有以下式子的逆转录病毒蛋白酶抑制剂：##STR1##。
• Intermediate for making retroviral protease inhibiting compounds
  申请人：Abbott Laboratories

  公开号：US05696270A1

  公开（公告）日：1997-12-09

  A retroviral protease inhibiting compound of the formula: ##STR1## is disclosed.

  公开一种化合物，其化学式为##STR1##，可抑制反转录病毒蛋白酶。
• Process for making retroviral protease inhibiting compounds
  申请人：Abbott Labortories

  公开号：US05892052A1

  公开（公告）日：1999-04-06

  A retroviral protease inhibiting compound of the formula: ##STR1## is disclosed.

  公开了一种化学式为##STR1##的逆转录病毒蛋白酶抑制剂。
• Processes and intermediates for manufacturing retroviral protease inhibiting compounds
  申请人：ABBOTT LABORATORIES

  公开号：EP1090914A2

  公开（公告）日：2001-04-11

  A retroviral protease inhibiting compound of formula (A) is disclosed for use in combination with other active pharmaceutical agents for treating a human infected by HIV. Intermediates and processes useful in the manufacture of compounds of formula (A) are also disclosed.

  本发明公开了一种抑制逆转录病毒蛋白酶的式(A)化合物，该化合物可与其他活性药剂联合使用，用于治疗受艾滋病毒感染的人。还公开了用于制造式（A）化合物的中间体和工艺。